Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
2666-3791
Volume Title
Publisher
Publisher DOI
Sponsorship
Wellcome Trust (207498/Z/17/Z)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Medical Research Council (G0701652)
Wellcome Trust (108070/Z/15/Z)